| Bioactivity | Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CLpro inhibitor[1][2][3][4]. |
| Invitro | Indinavir (0-50 µM; 18 h) blocks lymphocyte cell cycle in G0/G1 phase in PBMCs cells and impairs lymphoproliferative responses[1].Indinavir (40 µM-40 nM; 5 days) inhibits cell invasion and (40 µM-40 nM; 48 h) MMPs-2 activation of the Huh7 and SK-HEP-1 hepatocarcinoma cells in vitro[2]. Cell Viability Assay[1] Cell Line: |
| Name | Indinavir |
| CAS | 150378-17-9 |
| Formula | C36H47N5O4 |
| Molar Mass | 613.79 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Indinavir
CAS: 150378-17-9 F: C36H47N5O4 W: 613.79
Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Ind
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.